Cassava Sciences Inc【SAVA】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead...

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross...

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross...

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA)

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences...

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss...

Form 8-K - Current report

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before...

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the...

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The...

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences...

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The...

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The...

Form 4 - Statement of changes in beneficial ownership of securities

Steady_T 3週前

Something's afoot.... I think it's called pump and dump.

👍️ 1 🤣 2

urge2surge 4週前

Nervous? Just the messenger.. Volume suggests something's afoot imo.
Proven?? You sure about that?

💀 1 🤢 1 ☠️ 1

sunspotter 4週前

Why would any proper pharma company buy a scammy company with a drug candidate proven to be ineffective?

I think we can all safely discount those “rumors”.

👍️ 1

urge2surge 4週前

Biogen buyout rumors. Going to be a huge volume day here!

👍️0

urge2surge 1月前

Keep in mind the grand canyon gap on the chart. The reward to risk here favors upside including fomo momo.

👍️0

urge2surge 1月前

No ideas on what catalyst could be in play but there's short covering and institutional buying back in. Last day of tax loss selling is also fueling the buys. The obv is clearly indicating accumulations. Just my take

👍️0

ranchhand71 1月前

Or maybe this is year end retail flush dump capitulation… has the company downsized the staff in Austin? Any idea what their next act is?

👍️0

Steady_T 1月前

Based on what? Short squeeze could be epic here.

👍️0

urge2surge 1月前

Looks like bottom is in. Short squeeze could be epic here.

👍️0

ranchhand71 2月前

Majority of employees to be laid off?

👍️0

PonkenPlonken 2月前

Maybe they can save the company by saying they will turn into an AI drug discovery company and put their cash in BTC?
LOL

Yes, a company founded and run by fraudsters with a drug that doesn’t work.

What could possibly go wrong?

👍️ 1

ttottip 2月前

It's worth it to take a position here. There's a chance for rebound here.

😂 1

ranchhand71 2月前

In SEC 144 filing CFO using Morgan Stanley to sell SAVA stock . Saying he knows no material info!!!! Hmmm..

👍️0

PonkenPlonken 2月前

You are most welcome.
Maybe he is good at sniffing out security fraudsters and crooks because he knows how to think like them.
Regards...

👍️0

TheFinalCD 2月前

THANKS for the reply

I cant stand that weirdo either

he just happened to make a good call on $SAVA whether it was really him or not

who knows

👍️0

tredenwater2 2月前

What about the director who poured millions into Cassava propping it up when it would crash from bad news? If this was a scam, wouldnt he have known about it?

👍️0

PonkenPlonken 2月前

That also baffled me. Many smart people had their money tied up here and somehow the share price recovered after the court cases in September. Id love to know more about the why.
They didnt see the forest for all the trees?

👍️0

PonkenPlonken 2月前

I can only agree. Shkreli still has friends in the industry that likely told him about all of his "DD" that he presented in this rink dink "paper" then earns the laurels.
98% of PH3 Alzheimer trials miss and this one had many sticks in the soup. --> managements history of lying and no peer reviewed literatue backing.
Unbelievable there is this laughable antihero worshipping around his persona. Nothing fabulous about this sociopath.

👍️ 1

Hoskuld 2月前

I made the same call repeatedly over the last 2 years but didn't get the love that the convicted fraudster is getting!

👍️ 1

ranchhand71 2月前

How long before indictments of former CEO and his wife? Class action suit? Who sold with inside info this past Friday?

👍️0

TheFinalCD 2月前

I dont like him but he made a good pre P3 call
if somehow it passed P3 it could have went up slot
P3 fail it crashed

Im listening to him talk about shorting MSTR against BTC hedge/arbitrage
https://x.com/i/broadcasts/1LyxBgywQZkKN

👍️0

MartinLutherKing 2月前

Last call all aboard SAVA FDA fast track status Micro RNA novel prize cancer destruction RNAZ

👍️0

PonkenPlonken 2月前

When companies split in ways that put them this far above the minimum requirement they usually do so when they expect much more downside and when they want to cater to the low float crowd instead of real investors in the bio space.

👍️0

PonkenPlonken 2月前

Thank you. Someone forwarded this to me, else i wouldnt have anticipated something like that :)
Im not interested in ESPR right now as its really in no mans land. I dont "hold" many bios at all. The market has been brutal past few months. But there are some 70 stocks i monitor daily for action...

👍️0

FooBarAndGrill 2月前

$PGHL. Wow! Ran 918% during market hours. AH down 87%.
The opposite of a bear raid.
Prada
9 hours ago

So what happened? I’ll tell you….

Short sellers need only be outside of margin compliance for a fraction of a second for brokers to force automatic buy-ins. Knowing this, offshore scam operators tightly control the float of all these issuers but sometimes leave borrow available to lure in short sellers...

When short sellers bite, the scam operators wash trade a spike in the stock, then keep bid/asks moving during the halt so no unhalt price can be settled upon during regular trading hours. Then, after hours, it unhalts as they rip the price 10x+, causing brokers to force-liquidate accounts that were short. Brokers buy-in to cover the short sales as scam artists sell into the artificially high price.

This can lead to short accounts being wiped out instantly and can even lead to broker losses. The same liquidation scam playbook had been executed previously with other Nasdaq offshore scam tickers such as $ZJYL.

👍️0

dinogreeves 2月前

This is terrible

https://finance.yahoo.com/quote/PGHL/

👍️0

dinogreeves 2月前

So much for that former insider/fraudster of KBI*O then turned into another turd HYG*N. But altogether, SAVA has been a scam, any public company that works with Maxim is a scam. Period.

Exactly.

Nice chatting with you Janice.

👍️0

janice shell 2月前

Yes, I was surprised to learn kidney beans are somewhat toxic. Toxic enough that you should never cook them in the water you soaked them in. I wouldn't have known were I not an inveterate reader of packaging.

👍️0

FACT-MASTER 2月前

Cassava, from what i have seen, is ingrained into the cultures of Mexican / African / South American diets and they are proud of it.

Their persistence, imo comes from a lack of alternatives and again a culture practice of growing a usable and edible product. Visiting some places in Mexico / Brazil you begin to understand people are just in "survival" mode - use what's available.

The toxicity issue is also common in legume crops such as lima / red kidney beans which are also common in these cultural diets.

👍️0

janice shell 2月前

And it was first done by pretty primitive people.

👍️0

nsomniyak 2月前

Cocoa beans taste pretty crappy before you run them through a 15 step process to get chocolate...Another case of " how did they get from this raw stuff to that?"

👍️0

janice shell 2月前

Yes, it was an unusual choice of name. Though it's a popular carbohydrate in Central and South America, perhaps the most popular. I've always wondered how many people died before they figured out how to prepare it. And why they were so persistent.

👍️0

FACT-MASTER 2月前

Interesting, just like cassava, which when raw, contains cyanide and is toxic.

https://www.medicalnewstoday.com/articles/323756#is-it-toxic

The name picked by scammers for scammers - how suitable!

Now let's see , where is cassava grown? Mexico / Costa Rica / South America. Insiders probably went straight to the airport after the reverse split, never to be seen again, unless of couse Karma catches up to them, amen.

Appreciate the "scam force" here on Ihub - H Bear too.

👍️0

janice shell 2月前

Hello again! I found this one remarkable because it was KNOWN that the most important insiders were scammers. And people seem simply to have discounted that, somehow imagining what they produced would be a winner.

👍️0

FACT-MASTER 2月前

Why, hello janice!

Our paths have not crossed for a long time.

Yes, investors still gett'in burnt, will it ever end !? i think not, even i , have had to learn a few lessons from my foolish juvenile days. (lol)

👍️0

FACT-MASTER 2月前

Comprende amigo,

"Its possible for mortals to anticipate a partner in a ph1/ph2 company when their data is about to be due and a BP dropped similar but not equal programs recently"

(cost efficient for a BP to partner up with a smaller biotech demonstrating a superior product in the same category)

The reverse can also be true - eg IMTX, BMY drops out of 1 trial, IMA402 p1/p2 results are poor - same press release in that instance. Was suspicion evident in previous trading - i beleive so, however, hindsight is 20/20

👍️0

janice shell 2月前

Seriously, did anyone need Shkreli to tell them it was doomed? The follies of management should have been enough.

👍️ 1

FACT-MASTER 2月前

Congrats on your short here with SAVA.

Your education paid off big time in this instance!

We should probably discuss ESPR further on that board, of course if you are up to that.

👍️0

FACT-MASTER 2月前

Reminds me of of ARGS - that was a stinging lesson for me, ouch...still hurts!

Although i feel bad for investors in SAVA, biotech is high risk and that should be understood by all investors. Lawsuit won't help imo, ... prove wrongdoing against forward looking statements, etc, etc, for 5+ years, imo. - only good for the lawyers, imo.

Ref: Argos Therapeutics

👍️0

TheFinalCD 2月前

https://x.com/MartinShkreli/status/1859681514415607930

👍️0

MartinLutherKing 2月前

You will all kiss my feet brothers make it all back

👍️0

MartinLutherKing 2月前

Get ready for Fda fast track status for nobel prize micro rna for terminally ill cancer patients

👍️0

MartinLutherKing 2月前

A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.

👍️0

PonkenPlonken 2月前

I have never ever in my life seen a great bio with a chart like this.
SCREAMS promotion campaign - which is something you dont do when you have the next greatest thing in oncology.
Now a 1 for 33 is coming??

"The reverse split will reduce the number of shares of common stock outstanding from 17,265,658 shares to approximately 523,202 shares." per their recent PR. They want to cater to the low float crowd.
A more healthy ratio wouldve done it too...

👍️0

MartinLutherKing 2月前

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
“An SRC is a group of clinicians and experts that oversee the safety of subjects during the conduct of the trial. The SRC makes decisions on whether and how the study should proceed, including dose escalation and de-escalation decisions per the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “No dose-limiting toxicities were reported in the first cohort of patients treated with TTX-MC138. Eligible subjects may now be scheduled in Cohort 2 for treatment with the next dose level of TTX-MC138.”

👍️0

MartinLutherKing 2月前

Is FDA And NIH Ascam
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.

The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138. While efficacy of TTX-MC138 is not an endpoint in this trial, the trial may nevertheless provide early evidence of TTX-MC138 clinical activity in patients with metastatic disease. Funds under the grant are expected to be received over two years.

“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”

TTX-MC138 is a first-in-class therapeutic candidate with novel relevance to metastatic disease. Successful clinical development of TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター